INDICATIONS
Tivozanib is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

DOSAGE AND ADMINISTRATION
Recommended Dosing
The recommended dosage of Tivozanib is 1.34 mg taken orally once daily for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.

Continue treatment until disease progression or until unacceptable toxicity occurs.

Take Tivozanib with or without food. Swallow the Tivozanib capsule whole with a glass of water. Do not open the capsule.

If a dose is missed, the next dose should be taken at the next scheduled time. Do not take two doses at the same time.

Dose Modifications for Adverse Reactions
Initiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction.

If dose modifications are required for adverse reactions, reduce the dosage of Tivozanib to 0.89 mg for 21 days on treatment followed by 7 days off treatment for a 28-day cycle.

FIND A PRODUCT